Can Postmarketing Surveillance Help to Effect Optimal Drug Therapy?
- 30 November 1979
- journal article
- research article
- Published by American Medical Association (AMA)
- Vol. 242 (22) , 2420-2423
- https://doi.org/10.1001/jama.1979.03300220032019
Abstract
Postmarketing drug surveillance (PMS) assesses the epidemiology of drug use and monitors beneficial or harmful effects of drugs following marketing. If used systematically, PMS can substantially improve drug therapy in the United States. This can be accomplished by generating information on drug use and effects otherwise unavailable, by enabling a more efficient drug approval process, and by educating drug prescribers. However, to be successful, any PMS system will need a good deal of input from such prescribers. (JAMA242:2420-2423, 1979)Keywords
This publication has 4 references indexed in Scilit:
- Retrospective studies: A review for the clinician: Sartwell PE: Ann Int Med 81: 381–386, 1974Journal of Chronic Diseases, 1979
- Regular Aspirin Intake and Acute Myocardial InfarctionBMJ, 1974
- Evaluation of Spontaneous Reports of Adverse Reactions to DrugsBMJ, 1972
- The evaluation of new drugs. Current Food and drug Administration regulations and statistical aspects of clinical trialsArchives of internal medicine (1960), 1967